Publication date: Oct 31, 2024
An increase in Group A Streptococcus vulvovaginitis was detected in 2023: The average number of cases per year was 13 during 2011-2017. Twenty-five and 27 cases were reported in 2018 and 2019 followed by a decline coinciding with the COVID-19 pandemic. The 2023 increase surpassed previous data. The most frequent resistances were to erythromycin (11. 3%;) and tetracycline (8. 8%). Eleven different emm-types were detected among 30 GAS isolated in 2023: emm 1 was predominant (36. 7%) followed by emm 89 (20%), emm 87 (10%) and emm 28 (6. 7%). GAS should be increasingly considered in women with vulvovaginitis.
| Concepts | Keywords |
|---|---|
| Antibiotic | Antibiotic |
| Spain | Average |
| Women | Detected |
| Distribution | |
| Emm | |
| Gas | |
| Group | |
| Increase | |
| Reported | |
| Resistance | |
| Spain | |
| Streptococcus | |
| Type | |
| Vulvovaginitis | |
| Year |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | vulvovaginitis |
| disease | IDO | antibiotic resistance |
| disease | MESH | COVID-19 pandemic |
| drug | DRUGBANK | Erythromycin |
| drug | DRUGBANK | Tetracycline |
(Visited 1 times, 1 visits today)